Short-term single-centre experience with the HeartMate 3 left ventricular assist device for advanced heart failure.

Details

Serval ID
serval:BIB_7215FE6EDFAA
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Short-term single-centre experience with the HeartMate 3 left ventricular assist device for advanced heart failure.
Journal
European journal of cardio-thoracic surgery
Author(s)
Nowacka A., Hullin R., Tozzi P., Barras N., Regamey J., Yerly P., Rosner L., Marcucci C., Rusca M., Liaudet L., Kirsch M.
ISSN
1873-734X (Electronic)
ISSN-L
1010-7940
Publication state
Published
Issued date
01/09/2020
Peer-reviewed
Oui
Volume
58
Number
3
Pages
511-518
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
The objective of this study was to analyse clinical characteristics, survival and adverse events of patients with advanced heart failure supported using the Abbott HeartMate 3 left ventricular assist device (LVAD).
We retrospectively reviewed 42 consecutive HeartMate 3 recipients implanted in our centre between 1 November 2015 and 31 October 2019.
Our series comprised 39 males, aged 56.7 ± 11.8 years. Eleven (26%) patients had preimplant INTERMACS clinical profiles of 1 or 2. The mean duration support was 14.0 ± 10.6 months (range 0.69-44 months). During follow-up, 4 (10%) patients died while on support, 13 (35%) patients received a heart transplant and 25 patients are still ongoing. Actuarial survival after LVAD implantation was 88.4 ± 5.5% and 84.4 ± 6.6% at 1 and 2 years, respectively. There were no cases of pump thrombosis or technical malfunction. Seven (17%) patients required post-implant temporary right ventricular support. Adverse events included bleeding requiring surgery in 13 (31%) patients, gastrointestinal bleeding in 6 (14%) patients, LVAD-specific infections in 19 (45%) patients and non-disabling ischaemic stroke in 5 (12%) patients. The incidence of ischaemic stroke was significantly higher in patients where the outflow graft was anastomosed to the descending aorta as compared to those where it was anastomosed to the ascending aorta (P < 0.003).
We have observed satisfactory survival rates using the HeartMate 3 LVAD for long-term mechanical circulatory support. The absence of technical failure, pump thrombosis, haemolysis or need for pump exchange during our 4-year experience confirms its technical reliability and improved haemocompatibility, but bleeding complications and infections remain a concern.
Keywords
Complications, HeartMate 3, Left ventricular assist device, Survival
Pubmed
Web of science
Create date
04/04/2020 16:28
Last modification date
26/11/2020 7:26
Usage data